KRAS and neoplasm: Performance was low to moderate for tumor mutational burden (AUROC=0.67), APOBEC mutational signature (AUROC=0.57), and KRAS hotspot mutations (p.G12C: AUROC=0.74, p.G12V: AUROC=0.55, p.G12D: AUROC=0.43).